Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.

Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. Cancer. 2020 01 15; 126(2):432-443.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Biomarkers, Tumor
Carcinoma, Transitional Cell
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Inflammation
Male
Middle Aged
Patient Reported Outcome Measures
Quality of Life
Tumor Burden
Urinary Bladder Neoplasms
Young Adult

authors with profiles

Peter O'Donnell